HF Monitoring Partnerships Bodyport's proven HF monitoring program with Geisinger and its at-home cardiac scale enables hospitals and health systems to deploy scalable remote heart failure monitoring, potentially reducing readmissions and improving outcomes. This creates a compelling opportunity to partner with enterprise cardiology and population health teams across hospital networks.

Payer Cost Savings Bodyport's noninvasive hemodynamic biomarkers for predicting HF events offer a remote monitoring value proposition that aligns with payer initiatives focused on reducing hospitalizations and ED visits, creating a path for contract discussions with health plans and risk-bearing entities.

Clinical Trial Partnerships With SCALE-HF and ongoing biomarker validation, there are strong opportunities to collaborate with academic medical centers and CROs on evidence generation, enabling co-published results and broader adoption in trial settings.

Home Health Integration The at-home device platform fits into home health agencies and RPM ecosystems, providing clinicians with actionable hemodynamic insights between visits and supporting proactive management of fluid status in HF patients.

Cross-Condition Growth Beyond heart failure, Bodyport's biomarker platform could be extended to additional chronic conditions, offering enterprise customers a multi-disease digital biomarker solution and opportunities for upsell within existing accounts.